ARS Pharmaceuticals presents a strong investment opportunity with its FDA-approved needle-free epinephrine nasal spray, Neffy, aiming to disrupt the EpiPen market. With potential for significant market share and international expansion, ARS has room for growth despite stock price appreciation.